TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
作者信息
Kim Michael D, Salathe Matthias
机构信息
Department of Internal MedicineUniversity of Kansas Medical CenterKansas City, Kansas.
出版信息
Am J Respir Crit Care Med. 2020 Apr 15;201(8):888-889. doi: 10.1164/rccm.201912-2519ED.
Abstract
摘要
相似文献
1
TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?跨膜蛋白16A（TMEM16A）增强剂：囊性纤维化是否需要新型调节剂？
Am J Respir Crit Care Med. 2020 Apr 15;201(8):888-889. doi: 10.1164/rccm.201912-2519ED.
2
Small-molecule drugs for cystic fibrosis: Where are we now?用于治疗囊性纤维化的小分子药物：我们目前处于什么阶段？
Pulm Pharmacol Ther. 2022 Feb;72:102098. doi: 10.1016/j.pupt.2021.102098. Epub 2021 Nov 15.
3
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.用于治疗囊性纤维化的F508del-囊性纤维化跨膜传导调节因子校正剂：专利综述
Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15.
4
Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.治疗囊性纤维化跨膜电导调节因子缺陷型囊性纤维化患者。
Semin Respir Crit Care Med. 2019 Dec;40(6):762-774. doi: 10.1055/s-0039-1696664. Epub 2019 Oct 28.
5
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.突破性疗法：囊性纤维化（CF）增强剂和校正剂。
Pediatr Pulmonol. 2015 Oct;50 Suppl 40(0 40):S3-S13. doi: 10.1002/ppul.23240. Epub 2015 Jun 19.
6
Suppressing 'nonsense' in cystic fibrosis.
J Physiol. 2020 Feb;598(3):429-430. doi: 10.1113/JP279267. Epub 2020 Jan 16.
7
Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.优化囊性纤维化患者的护理和生活质量：囊性纤维化跨膜电导调节剂的影响。
Br J Hosp Med (Lond). 2021 Nov 2;82(11):1-6. doi: 10.12968/hmed.2021.0530. Epub 2021 Nov 22.
8
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.囊性纤维化跨膜传导调节因子调节剂：囊性纤维化治疗的现状与未来。综述
Arch Argent Pediatr. 2019 Apr 1;117(2):e131-e136. doi: 10.5546/aap.2019.eng.e131.
9
Potentiators for cystic fibrosis - targeting the underlying molecular defect.囊性纤维化的增效剂——针对潜在分子缺陷
Paediatr Respir Rev. 2015 Jun;16(3):162-4. doi: 10.1016/j.prrv.2015.04.003. Epub 2015 Apr 20.
10
Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.囊性纤维化跨膜转导调节因子增效剂作为有前途的囊性纤维化治疗方法。
Expert Opin Investig Drugs. 2011 Mar;20(3):423-5. doi: 10.1517/13543784.2011.554823. Epub 2011 Feb 9.
引用本文的文献
1
Update in Pediatrics 2020.《2020年儿科学进展》
Am J Respir Crit Care Med. 2021 Aug 1;204(3):274-284. doi: 10.1164/rccm.202103-0605UP.
本文引用的文献
1
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.TMEM16A 增强：囊性纤维化治疗的新策略。
Am J Respir Crit Care Med. 2020 Apr 15;201(8):946-954. doi: 10.1164/rccm.201908-1641OC.
2
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.囊性纤维化：高效靶向治疗药物的出现及其潜在的临床意义。
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO.
3
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
4
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
5
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.氯沙坦挽救囊性纤维化相关模型中炎症相关的纤毛黏液功能障碍。
Am J Respir Crit Care Med. 2020 Feb 1;201(3):313-324. doi: 10.1164/rccm.201905-0990OC.
6
SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.SPX-101 是一种新型靶向上皮钠离子通道的治疗药物，可恢复囊性纤维化的黏液转运。
Am J Respir Crit Care Med. 2017 Sep 15;196(6):734-744. doi: 10.1164/rccm.201612-2445OC.
7
Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction.钙激活氯离子通道 TMEM16A 调节粘蛋白分泌和气道平滑肌收缩。
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16354-9. doi: 10.1073/pnas.1214596109. Epub 2012 Sep 17.
8
Functional apical large conductance, Ca2+-activated, and voltage-dependent K+ channels are required for maintenance of airway surface liquid volume.功能性顶端的大电导、Ca2+激活和电压依赖性 K+ 通道对于维持气道表面液体量是必需的。
J Biol Chem. 2011 Jun 3;286(22):19830-9. doi: 10.1074/jbc.M110.185074. Epub 2011 Mar 31.
9
Expression cloning of TMEM16A as a calcium-activated chloride channel subunit.TMEM16A作为钙激活氯离子通道亚基的表达克隆
Cell. 2008 Sep 19;134(6):1019-29. doi: 10.1016/j.cell.2008.09.003.
10
TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity.TMEM16A，一种与钙依赖性氯离子通道活性相关的膜蛋白。
Science. 2008 Oct 24;322(5901):590-4. doi: 10.1126/science.1163518. Epub 2008 Sep 4.
Zotero 插件